Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel with or without sunitinib after EC/FEC for HER2-negative operable breast cancer
2009-009874-28Phase 3Terminated
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Sequential EC/FEC then docetaxel + sunitinib with Sequential EC/FEC then docetaxel + placebo (2 arms). Primary endpoint: pathologic complete response rate. Started Apr 2009; status: terminated.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-009874-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009874-28.